Literature DB >> 18510520

Inhibitor development.

J Astermark1, S Lacroix-Desmazes, M T Reding.   

Abstract

The immune response to factor VIII and the development of inhibitory antibodies is a complex multi-factorial process involving a variety of immune regulatory genes and cells, several of which have the potential to determine risk. A better understanding of the mechanisms involved will increase the likelihood of development of new therapeutic options for patients with hemophilia. This review summarizes genetic and non-genetic risk factors currently under evaluation, and the potential modulative effect of the von Willebrand factor on factor VIII immuno- and antigenicity. In addition, the role of T-regulatory cells in the pathogenicity of inhibitors will be discussed.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18510520     DOI： 10.1111/j.1365-2516.2008.01711.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  11 in total

1.  Lack of evidence of neoantigen formation in different batches of a double-virus inactivated factor VIII concentrate manufactured in Argentina.

Authors:  Hugo Guglielmone; Federico Farias; Cristian Moya; David Navarro; María Susana Vitali
Journal:  Blood Transfus       Date:  2010-09-14       Impact factor: 3.443

2.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Authors:  Jonathan D Finn; Margareth C Ozelo; Denise E Sabatino; Helen W G Franck; Elizabeth P Merricks; Julie M Crudele; Shangzhen Zhou; Haig H Kazazian; David Lillicrap; Timothy C Nichols; Valder R Arruda
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

3.  Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.

Authors:  Margaret V Ragni; Lynn M Malec
Journal:  Expert Rev Hematol       Date:  2014-11-05       Impact factor: 2.929

Review 4.  Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders.

Authors:  Kim Fechtel; Marika L Osterbur; Hildegard Kehrer-Sawatzki; Peter D Stenson; David N Cooper
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

5.  Removal of single-site N-linked glycans on factor VIII alters binding of domain-specific monoclonal antibodies.

Authors:  Jasmine Ito; Wallace Hunter Baldwin; Courtney Cox; John F Healey; Ernest T Parker; Emily R Legan; Renhao Li; Surinder Gill; Glaivy Batsuli
Journal:  J Thromb Haemost       Date:  2021-12-17       Impact factor: 5.824

6.  IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.

Authors:  Davide Matino; Marco Gargaro; Elena Santagostino; Matteo N D Di Minno; Giancarlo Castaman; Massimo Morfini; Angiola Rocino; Maria E Mancuso; Giovanni Di Minno; Antonio Coppola; Vincenzo N Talesa; Claudia Volpi; Carmine Vacca; Ciriana Orabona; Rossana Iannitti; Maria G Mazzucconi; Cristina Santoro; Antonella Tosti; Sara Chiappalupi; Guglielmo Sorci; Giuseppe Tagariello; Donata Belvini; Paolo Radossi; Raffaele Landolfi; Dietmar Fuchs; Louis Boon; Matteo Pirro; Emanuela Marchesini; Ursula Grohmann; Paolo Puccetti; Alfonso Iorio; Francesca Fallarino
Journal:  J Clin Invest       Date:  2015-08-31       Impact factor: 14.808

7.  Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.

Authors:  Ji Cheng; Alfonso Iorio; Maura Marcucci; Vadim Romanov; Eleanor M Pullenayegum; John K Marshall; Lehana Thabane
Journal:  J Blood Med       Date:  2016-10-25

8.  Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.

Authors:  Gouri Shankar Pandey; Chen Yanover; Tom E Howard; Zuben E Sauna
Journal:  PLoS Comput Biol       Date:  2013-05-16       Impact factor: 4.475

9.  Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.

Authors:  Andrea Annoni; Alessio Cantore; Patrizia Della Valle; Kevin Goudy; Mahzad Akbarpour; Fabio Russo; Sara Bartolaccini; Armando D'Angelo; Maria Grazia Roncarolo; Luigi Naldini
Journal:  EMBO Mol Med       Date:  2013-09-16       Impact factor: 12.137

10.  Induction of Hematopoietic Microchimerism by Gene-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy Products.

Authors:  Jérémie Martinet; Gwladys Bourdenet; Amine Meliani; Laetitia Jean; Sahil Adriouch; Jose L Cohen; Federico Mingozzi; Olivier Boyer
Journal:  Front Immunol       Date:  2016-09-15       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.